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Genetics and Microbiology, and 7Institute for Global Health and Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill; 8Medical Research Council 
Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom; 9Kinshasa School of Public Health, 
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Ghana
A better understanding of the drivers of the spread of malaria parasites and drug resistance across space and time is needed. These 
drivers can be elucidated using genetic tools. Here, a novel molecular inversion probe (MIP) panel targeting all major drug-resistance 
mutations and a set of microsatellites was used to genotype Plasmodium falciparum infections of 552 children from the 2013–2014 
Demographic and Health Survey conducted in the Democratic Republic of the Congo (DRC). Microsatellite-based analysis of popu-
lation structure suggests that parasites within the DRC form a homogeneous population. In contrast, sulfadoxine-resistance markers 
in dihydropteroate synthase show marked spatial structure with ongoing spread of double and triple mutants compared with 2007. 
These findings suggest that parasites in the DRC remain panmictic despite rapidly spreading antimalarial-resistance mutations. 
Moreover, highly multiplexed targeted sequencing using MIPs emerges as a cost-effective method for elucidating pathogen genetics 
in complex infections in large cohorts.
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Malaria, particularly drug-resistant malaria, remains a global 
public health problem [1]. However, little is known about the 
drivers that modulate its spread over space and time [2]. Over 
short distances, parasite distribution depends on both human 
and mosquito movement among local populations, but over 
larger distances, human population movement is the main 
determinant [3]. Understanding such movement is important 
in the context of malaria control, especially with regard to the 
spread of drug-resistant parasites [4–7].
The Democratic Republic of the Congo (DRC) is the second 
largest country by area in Africa, and it has the second high-
est malaria burden [1]. It is centrally located, bordering 9 other 
countries. Because of this, the flow of parasites between the 
DRC and its neighbors and within the DRC needs to be better 
understood. Previously, using 5 neutral microsatellites (MSs), 
we were able to show that Plasmodium falciparum parasites in 
the DRC were different from those in other countries, but we 
could not find any differentiation within the country [8, 9]. 
However, we found notable geographic structure in more 
recently introduced genotypes, such as those resistant to sulf-
adoxine [10]. Parasites that harbor recently described deletions 
in the pfhrp2 gene also showed spatial structure, clustering in a 
few sites in eastern DRC and in Kinshasa [11]. Based on these 
initial insights, information from more genetic markers and 
samples can likely further elucidate the population structure 
and flow of drug resistance.
Analyses of P. falciparum population genetics have been ham-
pered by several factors. First, the AT richness of the genome 
makes sequencing difficult [12]. Second, individuals are often 
infected with multiple genotypes, making haplotype recon-
struction challenging [13]. Third, balancing selection may inde-
pendently lead to identical parasite populations in geographic 
regions that are not spatially connected, thereby giving the false 
impression of high connectivity [14]. Finally, a substantial por-
tion of infections contain very low levels of circulating parasites, 
making it difficult to obtain enough parasite DNA relative to the 
human host for genotyping.
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Here we introduce a panel of molecular inversion probes 
(MIPs) that can alleviate some of these problems through 
cost-effective targeted sequencing at multiple loci. Molecular 
inversion probe sequencing is a novel tool that has been 
used extensively for targeted capture and resequencing of 
human candidate genes, allowing tens of thousands of indi-
vidual samples to be rapidly assessed at hundreds of loci 
(Figure  1A) [15–18]. Key strengths compared with other 
capture methods are scalability and minimal costs in terms 
of reagents and labor. Here, for the first time, we optimize 
MIPs for efficient capture from dried blood spots and use 
them to genotype and characterize malaria parasites across 
the DRC.
METHODS
Study Population
Dried blood spot samples were collected from children as part 
of cluster-based household surveys in the 2013–2014 DRC 
Demographic and Health Survey (DHS) from November 2013 
to February 2014, as described previously [19]. DNA samples 
were extracted from 1622 dried blood spots and analyzed for 
P. falciparum by real-time quantitative polymerase chain reac-
tion (qPCR). Each sample included global positioning system 
(GPS) coordinates that provide a location of the cluster of 
households from which they were collected [20]. The result-
ing 601 malaria-positive samples were selected and underwent 
MIP capture and sequencing at the University of Massachusetts. 
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Figure 1. Molecular inversion probe (MIP) assay and performance on laboratory control mixtures. A, The MIP capture is illustrated showing the key steps of MIP arm 
hybridization, polymerase extension, and gap ligation to form a single-stranded circle. Exonuclease digestion removes linear template DNA, thereby relatively enriching for 
the circular captures, which are then amplified using universal primers along with a sample barcode. Important components are color coded: extension arm (blue), ligation 
arm (red) molecular identifiers (green), and backbone (pink+purple). B, An example of microsatellite (MS) stutter seen in standard capillary electrophoresis versus MIPs 
where stutter is detected and removed based on inconsistency within unique molecular identifiers. C, The coverage of the 21 assessed MSs, demonstrating that apart from 
a few failed reactions the vast majority of MSs are detected in every sample until dilutions of 29 parasites/uL. D, Frequency estimates of the 4-strain mixture compared 
with expected frequency (last bar on right, drawn wider for emphasis) based on relative amounts of DNA from each strain. Abbreviations: CE, capillary electrophoresis; MIP, 
molecular inversion probe; MS, microsatellite.
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These positive samples came from 299 geographically distinct 
household cluster sites across all provinces within the country.
Control Samples
The sensitivity and accuracy of the MIP panel was assessed 
using serial dilutions of a control mixture of DNA isolated 
from the laboratory strains 3D7, HB3, 7G8, and DD2 mixed 
at relative frequencies of 67%, 14%, 13%, and 6%, respectively 
(Supplementary Tables 1 and 2). Quantification was based on 
Quant-iT PicoGreen dsDNA Assay (Invitrogen, catalog no. 
P11496). These DNA mixtures were supplemented with 1 ng/
µL of human DNA to better mimic DNA isolated from dried 
blood spots and whole blood and were included not only in ini-
tial testing but also as a positive control for every capture and 
sequencing run.
Plasmodium falciparum Molecular Inversion Probe Design
Molecular inversion probes are approximately 100 nucleotide 
long, single-stranded oligos that have a shared backbone and 
specific sequence complementary to the target region in the arms 
(Figure 1A, Supplementary Figure 1A). Plasmodium falciparum 
MIPs were designed to capture known and candidate drug-resis-
tance mutations (Table 1), as well as 11 previously described [21, 
22] and 18 newly designed flanking MSs (Yaobao et al., unpub-
lished data) (Table  2, Supplementary Table  3, Supplementary 
Methods). Nine of these MSs were removed from analysis for 
failing quality controls (Supplementary Methods).
Molecular Inversion Probe Capture, Amplification, and Sequencing
Our molecular inversion probe library sequencing is a multistep 
protocol modified from published protocols [23] to improve 
P. falciparum captures (Supplementary Methods, Supplementary 
Figures 1–4) with the following key steps. First a panel is created 
by pooling all desired MIPs (43 for MS MIP panel and 42 for 
drug-resistance MIP panel; Supplementary Table 3, probe sets 
MS1 and DR1, respectively), followed by 5’ end phosphoryla-
tion. Each panel can be used separately or combined to create 
a larger panel if desired. Each capture reaction is carried out as 
a single reaction per MIP panel per sample, combining sam-
ple DNA, MIP panel, polymerase, and ligase. With isothermal 
incubation, MIPs bind to their targets, followed by polymerase 
extension and single-stranded circle formation by ligase. After 
capture, all remaining linear DNA (unbound probes, original 
template DNA) is removed by exonuclease treatment. All cap-
tured products are then amplified by 1 forward and 1 reverse 
primer binding to the universal priming site on each circle. 
Polymerase chain reaction (PCR) primers also include Illumina 
sequencing adapters and 8-nucleotide-long sample barcodes. 
Once barcoded, samples are pooled into a single tube to create a 
sequence-ready library that is further cleaned prior to sequenc-
ing using solid phase reversible immobilization  (SPRI) beads 
and agarose gel purification (Supplementary Figure 1A).
Molecular Inversion Probe Data Processing
Sequencing data was processed using MIPWrangler software 
(Hathaway, unpublished data) in combination with other soft-
ware. Briefly, sequences were demultiplexed by their dual sam-
ple barcode using bcl2fastq software (Illumina). Paired-end 
reads were then stitched together using FLASH [24] and filtered 
on expected length and on per base quality scores by discard-
ing a sequence if the fraction of quality scores >30 was <70% 
(Q30 < 70%). Quality filtered stitched sequences were then fur-
ther demultiplexed by target using the extension and ligation 
arm sequences to produce a file for each target for each sample 
(Supplementary Figure 1B).
Target sequences for each sample were then corrected using 
their unique molecular identifiers (UMIs). This was done by 
clustering sequences on their UMIs and then creating a con-
sensus sequence for each specific UMI. This UMI redundancy 
removes a substantial proportion of PCR errors that occur 
in late cycles, including polymerase stutter and subsequent 
sequencing errors (Supplementary Figure  1B). The UMI cor-
rected sequences were then further clustered by using the qlus-
ter algorithm from SeekDeep, allowing accurate detection of 
single base differences and indels at levels ≤1% [25]. Given the 
variable depth, we set minimum threshold defaults at ≥2 UMIs 
and ≥0.5% relative abundance for a cluster to be included in 
final analysis.
Differences between the observed sequence and the reference 
sequence for each probe were obtained by pairwise alignment using 
LastZ software [26]. Single nucleotide variants and indels from the 
LastZ output were annotated using Annovar software [27].
Population Genetic Analyses of Microsatellites
Quality checks were carried out on the distribution of MS 
lengths, and all 20 loci were tested for independence through 
pairwise correlation tests using a Bonferroni-adjusted 
Table 1. Summary of Drug-Resistance Molecular Inversion Probes
Gene Targeted mutations Number of MIPs
PF3D7-1322700 T236I 1
PF3D7-1451200 N71 1
arps10 V127M 1
atp6 L263E, E431K, A623E, S769N 7
crt C72S, M74I, N75E, K76T, H97L, H97Y, 
A220S, N326S, I356T
7
cytb M133I, Y268S, Y268C, V284K 2
dhfr-ts A16V, N51I, C59R, S108T, I164L, T185 3
dhps S436A, A437G, K540E, A581G, A613S 2
fd D193Y 1
k13 M476I, Y493H, R539T, I543T, C580Y 9
mdr1 N86Y, Y184F, S1034C, N1042D, D1246Y 5
mdr2 T484I 1
pib7 C1484F 1
pph V1157L 1
Abbreviation: MIP, molecular inversion probe.
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significance threshold of α =0 05 190. /  to account for multiple 
testing. Principal component analysis (PCA) was conducted to 
look for any signal of population structure, using the dominant 
allele only in each individual and imputing missing values using 
the mean. Population structure was also assessed using the pro-
gram MavericK [28], which builds on the Bayesian mixture 
model approach developed by Pritchard and colleagues [29] 
but provides more accurate estimates of the number of clus-
ters. MavericK was run under the nonadmixture model with 
500 burn-in iterations, 10 000 sampling iterations, and 20 ther-
modynamic rungs. Finally, we looked for a signal of isolation 
by distance by regressing the absolute difference in MS lengths 
against geographic distance between sample GPS locations; 
under isolation by distance we would expect a positive relation-
ship between these quantities.
Spatial Analysis of Drug-Resistant Mutations
All drug-resistance loci were analysed separately using the R 
package PrevMap [30], which implements model fitting and 
spatial prediction under a range of geostatistical models. First, 
allele frequencies within each cluster were transformed to the real 
line using the transformation y log p pi i i= +( ) − +( )( )ε ε/ 1 , 
where pi  is the mutant allele frequency of cluster i , yi  is the 
transformed value, and ε  is a small value that ensures that yi  
values are always finite even when allele frequencies are 0 or 
1 (we used ε = 0 001. , although results were not highly sen-
sitive to this parameter). A  geostatistical model of the form 
y S x Zi i i= ( ) +  was then fit to the transformed data, where 
S x( )  is a stationary isotropic Gaussian process (GP) with vari-
ance σ 2  and Matérn correlation function with scale φ  and 
shape parameter κ = 2 , and Zi  is an independent Gaussian 
noise term with variance τ 2 . Hence, the 3 free parameters of 
the model were { , , }σ φ τ2 2 . These parameters were jointly esti-
mated in PrevMap using maximum likelihood, and fitted val-
ues were used to produce spatially continuous estimates of the 
underlying allele frequency distribution through 10 000 sim-
ulations. These simulations capture the predictive error that 
occurs due to the stochastic nature of the underlying model. 
Standard errors of prediction were calculated and used to mea-
sure confidence at each point in space.
Table 2. Summary of Microsatellite Molecular Inversion Probes
Region Chromosome Begin End Repeat unit Repeat type
No. of 
MIPs
No. of MIPs 
passing QC
AS1 chr11 416 541 416 572 AAT Trinucleotide 2 1
AS11 chr6 377 496 377 514 COMPLEX Trinucleotide 2 1
AS12 chr6 372 592 372 612 AAT Trinucleotide 2 1
AS13 chr6 372 579 372 621 ATA Trinucleotide 1 1
AS14 chr5 1 218 960 1 218 986 AAC, AAT, ATTATGATA Trinucleotide 2 2
AS15 chr13 2 587 730 2 587 758 ATA Trinucleotide 2 1
AS19 chr4 533 507 533 554 ATA, ATT Trinucleotide 2 2
AS2 chr11 416 832 416 890 AAT Trinucleotide 2 1
AS20 chr4 536 917 536 949 TAA Trinucleotide 1 0
AS21 chr4 528 577 528 599 TTA Trinucleotide 2 0
AS25 chr10 1 324 819 1 324 890 ATT,ACT Trinucleotide 1 0
AS3 chr11 417 708 417 739 TAA Trinucleotide 2 0
AS31 chr6 806 342 806 371 ATT Trinucleotide 1 1
AS32 chr12 1 623 232 1 623 297 ATT Trinucleotide 1 1
AS34 chr12 2 034 957 2 034 977 ATT,ACT Trinucleotide 2 1
AS4 chr11 418 074 418 095 TAA Trinucleotide 2 2
AS7 chr6 899 277 899 296 ATT Trinucleotide 1 1
AS8 chr6 894 235 894 269 ATT Trinucleotide 2 2
Ara2 chr11 416 315 416 359 TAA Trinucleotide 2 2
B7M19 chr10 1 356 173 1 356 265 T Mononucleotide 2 1
PFG377 chr12 2 045 854 2 045 894 TAT Trinucleotide 2 1
PfPK2 chr12 1 611 244 1 611 352 TAA Trinucleotide 1 0
PolyAlpha chr4 532 213 532 302 ATT Trinucleotide 1 0
TA1 chr6 899 867 900 004 TAT Trinucleotide 1 0
TA109 chr6 801 053 801 073 ACT, AATAATGATAAT Trinucleotide 2 1
TA40 chr10 1 322 613 1 322 772 AAT Trinucleotide 1 1
TA60 chr13 2 588 764 2 588 796 AAT Trinucleotide 2 1
TA81 chr5 1 214 362 1 214 391 ATA Trinucleotide 2 1
TA87 chr6 374 755 374 808 AAC, AAT Trinucleotide 1 0
Abbreviations: MIC, molecular inversion probe; QC, quality control.
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RESULTS
Molecular Inversion Probe Performance Controls
The accuracy and sensitivity of the designed MIP assay were 
tested using 15 serial dilutions of a DNA mixture of 4 labo-
ratory strains (Supplementary Table  1) containing from 7469 
down to 0.5 of Plasmodium haploid genome copies and 1  ng 
of human DNA (~1650 haploid genome copies) per microliter. 
Unique molecular identifiers associated with each arm allowed 
correction of errors introduced during PCR amplification 
(Supplementary Figure 1B), including MS stutter (Figure 1B). 
Based on these control mixtures, MIPs captured the vast major-
ity of targets down to inputs of approximately 29 parasites per 
microliter (Figure 1C). The frequency estimates were consistent 
down to approximately 29 parasites per microliter, closely fol-
lowing the expected frequencies based on picogreen quantifica-
tion of input DNA (Figure 1D).
Sequencing the Parasitemic Demographic and Health Survey Blood Spots
Among these 601 samples submitted for analyses, after a single 
MIP capture and sequencing run each for the drug-resistance 
and MS panels, 552 samples yielded a usable sequence. The 
sequenced individuals were well distributed across the country 
(Figure 2). Overall, 293 and 154 samples showed good coverage 
of 50% and 80%, respectively, across all of the targeted loci. In 
terms of density of infection, we found that MIP coverage began 
to drop off at qPCR cycle threshold  (Ct) values of 31, which 
equates to a parasite level of approximately 100 parasites/uL 
(Supplementary Figure 5). This represents low parasitemia but 
may also be a consequence of the quality of the dried blood spots, 
as well as the large number of samples multiplexed. The median 
Ct value of the samples that yielded no MIP coverage was 34. The 
raw sequence data used in this study has been deposited to 
Sequence Read Archive of National Center for Biotechnology 
Information with the accession number SRP144456.
Microsatellite Population Genetics
We first explored population structure using the 20 well-val-
idated MSs from the MIP panel. Consistent with their known 
sequence, 19 MSs showed clear trinucleotide repeat distribu-
tions, with only MS B7M19 having a more complex repeat dis-
tribution (Supplementary Figure 6). Among the 19 trinucleotide 
MSs, just 2 of 7515 MS length calls fell outside the trinucleo-
tide pattern, and these were removed from subsequent analyses. 
There was correlation in MS lengths in only 2 of the 190 pair-
wise comparisons—between Ara2 and AS1 and between AS12 
and AS13. These MSs occur in close physical proximity, so this 
correlation indicates likely linkage disequilibrium. Principal 
component analysis indicated no clear signal of population 
structure, and the first 2 components accounted for a mini-
mal amount of the total variation in the data (17% for PCA1, 
14% for PCA2) (Figure  3, Supplementary Figure  7). Analysis 
in MavericK also failed to detect any population structure, with 
K = 1 clusters having the highest model evidence, indicating a 
single freely mixing population (Supplementary Figure 8). This 
was further supported by regression of genetic and geographic 
distance, which revealed no strong signal of isolation by distance 
(Supplementary Figure 9).
Drug-Resistance Profiling
Using the MIPs we designed to target known and putative 
drug-resistance mutations based on the literature. We first, quan-
tified the prevalence of known drug-resistance mutations. The 
pfdhfr-ts gene mutations N51I, C59R, and S108N showed the 
highest prevalence (>80%) among all tested drug-resistance loci. 
Similar to the previous studies, the levels of evolutionarily older 
pfdhps mutations A437G and K540E showed higher prevalence 
compared with A581G [10, 31]. The mutations A613S/T and 
I431V seen in Western Africa [32] were not observed in the DRC. 
Mutations at the highest prevalences include those in pfcrt and 
pfmdr1. Importantly, known artemisinin-resistance mutations in 
pfk13 (M476I, Y493H, R539T, I543T, C580Y) were not observed 
in any sample (Figure 4; Supplementary Table 6) consistent with 
previous studies [33, 34]. With deep sequencing, in addition to 
prevalence, we can also examine overall population frequencies 
of mutations. As expected, mutant allele frequencies were nearly 
identical to prevalences (Supplementary Figure 10) [35, 36].
Spatial Assessment of Drug Resistance
Given the country-wide sampling scheme, we modeled the 
spatially referenced prevalence data using PrevMap to look for 
Figure 2. Distribution of 552 children with captured sequence. These samples 
were distributed across the Democratic Republic of the Congo without significant 
differences in the spatial distribution compared with the overall sample set or to 
the overall Demographic and Health Survey. The circle diameter is proportional to 
the number of samples from a given GPS location.
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differences based on geographic location. For each mutation, we 
generated estimated prevalences and standard errors of predic-
tion (Supplementary Figures 11 and 12). These predictions are 
generated using the maximum likelihood model parameters, 
so, although we present the most likely prevalence surfaces, it 
is important to emphasize there are alternative predictive sur-
faces that are plausible. Various spatial patterns were observed. 
Generally, older initial mutations or mutations that confer resis-
tance to previous generations of drugs were relatively uniform 
in distribution. For instance, key mutations for chloroquine 
resistance and pyrimethamine resistance had relatively uniform 
prevalences across the DRC. Interestingly, what are thought to 
be relatively more recent adaptive mutations associated with sul-
fadoxine resistance showed strong spatial structure (Figure  5). 
The pfdhps K540E mutation was predominantly localized in the 
northeast, and, interestingly, the pfdhps A581G mutation was 
always found against a background of K540E. Conversely, the 
A437G mutation is seen in association with K540E and A581G 
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mutations, as well as a single mutant pfdhps in the western side 
of the country. The S436A variant, not associated with drug 
resistance, occurs at high prevalence in the north of the coun-
try toward central Africa where it is most prevalent [37]. For 
pfdhps, the frequency of parasite mutations has significantly 
changed in comparison with our previous assessment of the 
2007 DHS (P = 2.6 × 10−5, χ2 test, 3 df) [10]. Filtering our data 
to nonmixed pfdhps haplotypes equivalent to the 2007 analysis, 
the overall frequency of mutant parasites has increased mark-
edly (43.5% in 2007 vs 72.1% in 2013; P = 1.5 × 10−6, Fisher exact 
test). The number of strains with sequential mutations, double 
pfdhps mutations (436S/437G/540E/581A—SGEA), and triple 
pfdhps  mutations (SGEG) has increased significantly from 14.6% 
to 27.2% (P  =  .009). Overall, the single (SGKA and AGKA), 
double (SGEA), and triple (SGEG) mutants have increased 1.5-, 
1.8-, and 2.2-fold, respectively, consistent with a greater selective 
advantage for triple mutant, fitting with its rapid spread where 
it was only observed approximating the northeast border in the 
2007 DHS.
DISCUSSION
Making statistically robust inferences from population genet-
ics has been challenging for malaria. Many P. falciparum pop-
ulation genetic studies have used convenience samples, which 
may not be representative of the true parasite population and 
have the potential for substantial selection bias. Accordingly, we 
have used samples taken from the 2013–2014 DHS, which was 
a cluster-based household survey designed to be representative 
of the national population as a whole. To our knowledge, this 
is the first study to attempt to use a population-based sample 
of the malaria parasite to understand its subpopulation and 
drug-resistance structure and possible mechanisms of gene flow 
in the DRC.
Our results indicate that the parasite population is best 
characterized as a single population that exhibits weak isola-
tion-by-distance. This is perhaps surprising given the country’s 
poor infrastructure and transportation network, which should 
lead to differentiation over relatively short spatial scales. Hence, 
it may be the case that transmission in the DRC is too high 
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to measure differences in gene flow by traditional methods, 
with high levels of heterozygosity and the accompanying high 
genetic variability meaning that noise dominates any potential 
signal in the data.
In contrast, mutations in the pfdhps gene are very hetero-
geneously distributed and appear to be predominantly mov-
ing east to west with proportionally faster spread of the most 
resistant mutations. The pfdhps K540E mutation is concentrated 
in the eastern DRC, much more so than found previously in 
samples from the 2007 DHS [10]. Alarmingly, our data show 
that the pfdhps A581G mutation, observed in 2007, has further 
spread within the eastern DRC, now with a prevalence of 12.6% 
of infections with an allele frequency in the parasite popula-
tion that has doubled from 3.3% to 7.4% frequency in a 6-year 
span. This combination of the A437G, K540E, and A581G triple 
mutations (GEG) is particularly ominous in that it is predictive 
of the failure of intermittent preventive therapy in pregnancy 
(IPTp) with sulfadoxine pyrimethamine  (SP). The GEG triple 
mutant haplotype emerged in Tanzania in 2006, causing SP 
treatment failure when used for intermittent preventive treat-
ment of malaria in infants [38]. It has since been reported in 
multiple countries in East Africa, including Rwanda, Uganda, 
Zambia, Malawi, Ethiopia, and the DRC [39–43], but is missing 
in West Africa [44–46]. Overall, the rates of increase in allele 
frequencies correlate with the number of mutations, consistent 
with the likely increased fitness conferred by sequential muta-
tions. Although SP was no longer recommended as a first-line 
antimalarial in the DRC, the selective pressure may have been 
exerted by continued private sector use in addition to IPTp. 
A 2013 survey in Kinshasa showed that SP was the second most 
distributed treatment (31.1%) after non–quality-assured arte-
misinin combination therapy (38.5%) and indicated that SP 
may be being used as an inexpensive alternative to artemisinin 
combination threapy (ACT) outside of IPTp use [47]. Although 
more recent reports suggest that ACT availability has increased, 
the second most common partner drug in ACTs was SP (31.2%) 
in private pharmacies that provide the vast majority of antima-
larials [48]. Providing maps, such as these, to national malaria 
control programs, should facilitate the appropriate choice of 
antimalarials at a local level.
The methods described here have a number of advantages 
over existing molecular surveillance platforms. First, MIPs min-
imize sequencing errors and can be used on small samples, such 
as dried blood spots. Second, the MIP platform we have devel-
oped is highly modular and scalable, so it can be expanded to 
include hundreds or thousands of additional targets and obtain 
much richer genetic data. Addition of new targets requires sim-
ply the design and synthesis of new oligos that can be added 
to existing panels. Molecular inversion probes also minimize 
effort and costs. For this study the work consumed 24 hours 
of technician time and $5000 in reagent and sequencing costs. 
Finally, all previous studies aggregate case reports or individual 
studies [31]; building on a nationally representative survey, 
such as the DHS, allows the calculation of local prevalences not 
only for malaria but also for drug-resistant malaria.
There are several other methods that have been used for mea-
suring population structure in P.  falciparum, including single 
nucleotide polymorphism (SNP) barcodes and whole genome 
analyses [49, 50]. Although useful, both of these methods have 
limitations. First, SNPs used in SNP barcodes are limited to 
those that are amenable to TaqMan genotyping assay and have 
limited ability to detect minority variants. Second, the assays 
are carried out individually for each genomic target, making 
the approach unscalable to large numbers of targets. Third, the 
information obtained from the SNP barcodes is limited to the 
known polymorphic SNPs and is insensitive to novel sequence 
variations. Whole genome sequencing, on the other hand, while 
addressing the limitations of SNP barcodes, is still too expen-
sive to use for large cohorts. Furthermore, it is very difficult to 
assemble genomes from infections with a mixture of genotypes. 
Additionally, the host DNA contamination in most samples 
makes it hard to get good coverage of parasite DNA, especially 
in nonsymptomatic, low-parasite-density infections.
Importantly, this study has limitations. First, the low-den-
sity infections are difficult to sequence and are less represented 
compared with higher-density infections. Second, this study 
relied on data sampled from children rather than across all ages. 
Finally, the methods used for the DRC, a very high transmission 
country, may not be directly applicable to countries with lower 
malaria transmission. Nevertheless, the MIP protocol used here 
allows for genotyping of malaria parasites at scale, both in terms 
of number of samples and number of loci. As such, it should 
prove useful for other objectives in molecular surveillance—for 
example of known drug-resistant or other mutations of public 
health importance.
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